Andrés Cervantes

61.4k total citations · 18 hit papers
468 papers, 27.8k citations indexed

About

Andrés Cervantes is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Andrés Cervantes has authored 468 papers receiving a total of 27.8k indexed citations (citations by other indexed papers that have themselves been cited), including 336 papers in Oncology, 160 papers in Pulmonary and Respiratory Medicine and 103 papers in Surgery. Recurrent topics in Andrés Cervantes's work include Colorectal Cancer Treatments and Studies (165 papers), Gastric Cancer Management and Outcomes (87 papers) and Cancer Treatment and Pharmacology (67 papers). Andrés Cervantes is often cited by papers focused on Colorectal Cancer Treatments and Studies (165 papers), Gastric Cancer Management and Outcomes (87 papers) and Cancer Treatment and Pharmacology (67 papers). Andrés Cervantes collaborates with scholars based in Spain, United States and France. Andrés Cervantes's co-authors include Dirk Arnold, Bernard Nordlinger, Emmanuel Tiret, Eric Van Cutsem, David Cunningham, William Allum, Marcel Verheij, Bengt Glimelius, Rob Glynne‐Jones and Josep Tabernero and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Andrés Cervantes

448 papers receiving 27.3k citations

Hit Papers

Leucovorin and Fluorourac... 2000 2026 2008 2017 2000 2013 2017 2010 2013 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
    2000 3.0k citations Andrés Cervantes et al. Journal of Clinical Oncology profile →
  2. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2013 1.4k citations Bengt Glimelius, Emmanuel Tiret et al. Annals of Oncology profile →
  3. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2017 1.3k citations Rob Glynne‐Jones, Lucjan Wyrwicz et al. Annals of Oncology profile →
  4. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2010 1.1k citations David Cunningham, Andrés Cervantes et al. Annals of Oncology profile →
  5. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2013 1.1k citations Roberto Labianca, Andrés Cervantes et al. Annals of Oncology profile →
  6. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2016 1.1k citations David Cunningham, Andrés Cervantes et al. Annals of Oncology profile →
  7. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2014 880 citations Eric Van Cutsem, Andrés Cervantes et al. Annals of Oncology profile →
  8. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
    2022 774 citations Andrés Cervantes, R. Adam et al. Annals of Oncology profile →
  9. Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
    2010 755 citations Marc Peeters, Timothy Price et al. Journal of Clinical Oncology profile →
  10. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2018 712 citations Andrés Cervantes, Ian Chau et al. Annals of Oncology profile →
  11. OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study
    2006 583 citations Andrés Cervantes, Marc Buyse et al. Journal of Clinical Oncology profile →
  12. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials
    2017 554 citations Dirk Arnold, Jean-Yves Douillard et al. Annals of Oncology profile →
  13. Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)
    2011 452 citations Éric Pujade-Lauraine, Michael Quinn et al. profile →
  14. Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up
    2014 386 citations Rob Glynne‐Jones, Andrés Cervantes et al. profile →
  15. Clinical management of metastatic colorectal cancer in the era of precision medicine
    2022 336 citations Fortunato Ciardiello, Josep Tabernero et al. profile →
  16. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines
    2021 306 citations Erika Martinelli, Andrés Cervantes et al. Annals of Oncology profile →
  17. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
    2022 293 citations Andrés Cervantes, Florian Lordick et al. Annals of Oncology profile →
  18. Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage SCLC: Results From TROPiCS-03
    2025 18 citations Andrés Cervantes, Antoîne Italiano et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrés Cervantes Spain 68 18.1k 9.4k 8.4k 4.2k 3.9k 468 27.8k
Olivier Bouché France 60 18.6k 1.0× 9.5k 1.0× 8.0k 1.0× 2.8k 0.7× 2.7k 0.7× 418 25.3k
Ian Chau United Kingdom 56 13.1k 0.7× 7.2k 0.8× 5.4k 0.6× 2.6k 0.6× 2.6k 0.7× 473 18.8k
Marc Ychou France 59 16.1k 0.9× 7.7k 0.8× 4.8k 0.6× 4.2k 1.0× 2.8k 0.7× 322 22.1k
Filippo de Braud Italy 74 17.9k 1.0× 8.8k 0.9× 5.6k 0.7× 5.7k 1.4× 3.3k 0.9× 754 26.7k
Yoon‐Koo Kang South Korea 69 12.3k 0.7× 13.6k 1.5× 6.9k 0.8× 5.2k 1.2× 3.8k 1.0× 550 26.2k
Hyun Cheol Chung South Korea 64 15.2k 0.8× 14.1k 1.5× 7.2k 0.9× 5.7k 1.3× 3.0k 0.8× 603 27.8k
Daniel G. Haller United States 68 16.8k 0.9× 9.2k 1.0× 8.7k 1.0× 2.6k 0.6× 4.6k 1.2× 243 25.2k
Al B. Benson United States 94 18.9k 1.0× 8.7k 0.9× 8.7k 1.0× 3.5k 0.8× 4.5k 1.1× 492 31.0k
Herbert I. Hurwitz United States 71 17.8k 1.0× 7.8k 0.8× 3.7k 0.4× 8.0k 1.9× 3.0k 0.8× 319 26.8k
Valérie Boige France 63 9.5k 0.5× 6.2k 0.7× 5.7k 0.7× 2.5k 0.6× 2.4k 0.6× 287 17.6k

Countries citing papers authored by Andrés Cervantes

Since Specialization
Citations

This map shows the geographic impact of Andrés Cervantes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrés Cervantes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrés Cervantes more than expected).

Fields of papers citing papers by Andrés Cervantes

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrés Cervantes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrés Cervantes. The network helps show where Andrés Cervantes may publish in the future.

Co-authorship network of co-authors of Andrés Cervantes

This figure shows the co-authorship network connecting the top 25 collaborators of Andrés Cervantes. A scholar is included among the top collaborators of Andrés Cervantes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrés Cervantes. Andrés Cervantes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Oltra, Sara S., Maider Ibarrola‐Villava, Elena Jiménez-Martí, et al.. (2022). RUNAT-BI: A Ruthenium(III) Complex as a Selective Anti-Tumor Drug Candidate against Highly Aggressive Cancer Cell Lines. Cancers. 15(1). 69–69. 3 indexed citations
2.
Cervantes, Andrés, R. Adam, Susana Roselló, et al.. (2022). Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology. 34(1). 10–32. 774 indexed citations breakdown →
3.
Pellino, Gianluca, Matteo Frasson, Javier Escrig‐Sos, et al.. (2020). Impact of perioperative transfusions and sepsis on long-term oncologic outcomes after curative colon cancer resection. A retrospective analysis of a prospective database. Gastroenterología y Hepatología. 43(2). 63–72. 1 indexed citations
4.
Bahleda, Rastislav, Antoîne Italiano, Cinta Hierro, et al.. (2019). Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. Clinical Cancer Research. 25(16). 4888–4897. 187 indexed citations
5.
Tarazona, N., Francisco Gimeno-Valiente, Valentina Gambardella, et al.. (2019). Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. Annals of Oncology. 30(11). 1804–1812. 190 indexed citations
6.
Gambardella, Valentina, Francisco Gimeno-Valiente, Noelia Tarazona, et al.. (2018). NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in HER2 -Amplified Gastric Cancer. Clinical Cancer Research. 25(5). 1639–1649. 55 indexed citations
7.
Dickler, Maura N., Cristina Saura, Donald Richards, et al.. (2018). Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer. Clinical Cancer Research. 24(18). 4380–4387. 57 indexed citations
8.
Sobrero, Alberto, Axel Grothey, Timothy Iveson, et al.. (2018). The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?. Annals of Oncology. 29(5). 1099–1107. 27 indexed citations
9.
Glynne‐Jones, Rob, Lucjan Wyrwicz, Emmanuel Tiret, et al.. (2017). Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 28(suppl_4). iv22–iv40. 1290 indexed citations breakdown →
10.
Tabernero, Josep, Malvika Vyas, Rosa Giuliani, et al.. (2016). Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. ESMO Open. 1(6). e000142–e000142. 88 indexed citations
11.
Dienstmann, Rodrigo, Amita Patnaik, Rocio García‐Carbonero, et al.. (2015). Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. Cancer Discovery. 5(6). 598–609. 58 indexed citations
12.
Cosimo, Serena Di, Sriram Sathyanarayanan, Johanna C. Bendell, et al.. (2014). Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial. Clinical Cancer Research. 21(1). 49–59. 48 indexed citations
13.
Sclafani, Francesco, Amitesh Roy, David Cunningham, et al.. (2013). HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab. Annals of Oncology. 24(12). 3123–3128. 30 indexed citations
14.
Cervantes, Andrés, Élena Elez, Desamparados Roda, et al.. (2012). Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 18(17). 4764–4774. 119 indexed citations
15.
16.
Tabernero, Josep, Luc Dirix, Patrick Schöffski, et al.. (2011). A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors. Clinical Cancer Research. 17(19). 6313–6321. 46 indexed citations
17.
Peeters, Marc, Timothy Price, Andrés Cervantes, et al.. (2010). Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology. 28(31). 4706–4713. 755 indexed citations breakdown →
18.
Baselga, José, Andrés Cervantes, Erika Martinelli, et al.. (2010). Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors. Clinical Cancer Research. 16(19). 4876–4883. 95 indexed citations
19.
Abad, Albert, Alfredo Carrato, Matilde Navarro, et al.. (2005). Two Consecutive Phase II Trials of Biweekly Oxaliplatin plus Weekly 48-Hour Continuous Infusion of Nonmodulated High-Dose 5-Fluorouracil as First-Line Treatment for Advanced Colorectal Cancer. Clinical Colorectal Cancer. 4(6). 384–389. 7 indexed citations
20.
Quinn, Michael, Jacobus Pfisterer, Michael A. Bookman, et al.. (2005). Integration of new or experimental treatment options and new approaches to clinical trials. Annals of Oncology. 16. viii30–viii35. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Olivier Bouché Breakdown of academic impact, for papers by Ian Chau Breakdown of academic impact, for papers by Marc Ychou Breakdown of academic impact, for papers by Filippo de Braud Breakdown of academic impact, for papers by Yoon‐Koo Kang Breakdown of academic impact, for papers by Hyun Cheol Chung Breakdown of academic impact, for papers by Daniel G. Haller Breakdown of academic impact, for papers by Al B. Benson Breakdown of academic impact, for papers by Herbert I. Hurwitz Breakdown of academic impact, for papers by Valérie Boige
Rankless by CCL
2026